Loading...
•
Dec 31, 2022
Exact Sciences Q4 2022 Earnings Report
Reported record revenue and anticipated continued growth in 2023.
Key Takeaways
Exact Sciences reported a 17% increase in total revenue for Q4 2022, reaching $553 million. Screening revenue was $404 million and Precision Oncology revenue was $143 million. The company anticipates revenue of $2,265-$2,315 million and positive adjusted EBITDA for full year 2023.
Total fourth quarter revenue was $553 million, an increase of 17% or 28% excluding COVID-19 testing.
Screening revenue was $404 million and Precision Oncology revenue was $143 million.
Gross margin including amortization of acquired intangible assets was 70 percent, and non-GAAP gross margin excluding amortization of acquired intangible assets was 73 percent.
Net loss was $127.7 million, or $0.72 per share.
Exact Sciences
Exact Sciences
Exact Sciences Revenue by Segment
Revenue by Segment
Screening Revenue
CapyFin.comPrecision Oncology Revenue
CapyFin.com Forward Guidance
The company anticipates revenue of $2,265-$2,315 million during 2023.
Positive Outlook
- Screening revenue of $1,660-$1,690 million
- Precision Oncology revenue of $600-$620 million
- COVID-19 testing revenue of $5 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income